The startup develops targeted therapies for central nervous system disorders and substance use disorders, focusing on reducing barriers to treatment access. By addressing significant gaps in effective medical care, the company aims to improve patient health outcomes in these underserved areas.
Funding
$14.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Millions of individuals experience distress and discomfort when attempting to discontinue cannabis use, yet there are currently no FDA-approved medications to treat Cannabis Use Disorder (CUD) and Cannabis Withdrawal Syndrome (CWS). This lack of effective treatments poses a significant impediment to discontinuing cannabis use, leading to continued suffering and limited recovery options.
Solution
PleoPharma is developing novel, safe, and effective FDA-approved medications to address the unmet needs in treating addiction and withdrawal, specifically targeting substance use disorders where current therapies are lacking. Their lead program, PP-01, is an oral prescription medication designed to mitigate cannabis withdrawal symptoms in adolescents and adults with CUD and has completed Phase 2 clinical trials. By filling this therapeutic void, PleoPharma aims to make a meaningful contribution to society by enabling recovery for individuals struggling with cannabis addiction and withdrawal. The company's first-to-market strategy focuses on securing strong payor coverage and establishing a viable commercial opportunity for new indications in well-established addiction diseases.
Target Audience
PleoPharma's primary target audience includes individuals seeking treatment for cannabis use disorder and cannabis withdrawal syndrome, as well as healthcare providers, support groups, and clinical sites involved in addiction treatment.
Features
- PP-01: An oral prescription medication in development for mitigating cannabis withdrawal symptoms.
- Focus on obtaining FDA approval for novel medications targeting substance use disorders.
- First-to-market strategy to address therapeutic voids where no FDA-approved therapies currently exist.
- Clinical trials conducted to evaluate the safety and efficacy of investigational new drugs.
- Expanded access program to provide investigational drugs to patients with serious conditions when available and appropriate.